Iridian Asset Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $8.32M | Sell |
45,129
-2,795
| -6% | -$608K | 3.03% | 9 |
|
|
2026
Q2 | $11.7M | Sell |
47,924
-19,567
| -29% | -$4.24M | 4.03% | 9 |
|
|
2026
Q1 | $11.4M | Sell |
67,491
-6,292
| -9% | -$1.09M | 4.62% | 8 |
|
|
2025
Q4 | $13.5M | Sell |
73,783
-9,770
| -12% | -$1.36M | 4.96% | 8 |
|
|
2025
Q3 | $10.1M | Sell |
83,553
-8,208
| -9% | -$925K | 3.99% | 10 |
|
|
2025
Q2 | $9.6M | Sell |
91,761
-14,551
| -14% | -$1.54M | 3.32% | 9 |
|
|
2025
Q1 | $12.4M | Sell |
106,312
-18,767
| -15% | -$2.14M | 3.89% | 9 |
|
|
2024
Q4 | $10.6M | Sell |
125,079
-1,724
| -1% | -$159K | 2.82% | 12 |
|
|
2024
Q3 | $11.4M | Sell |
126,803
-102
| -0.1% | -$8.9K | 2.44% | 15 |
|
|
2024
Q2 | $10.2M | Sell |
126,905
-1,937
| -2% | -$143K | 2.31% | 16 |
|
|
2024
Q1 | $10.3M | Sell |
128,842
-9,495
| -7% | -$797K | 2.02% | 14 |
|
|
2023
Q4 | $11M | Sell |
138,337
-6,696
| -5% | -$448K | 2% | 12 |
|
|
2023
Q3 | $10.1M | Sell |
145,033
-167,375
| -54% | -$12.5M | 2.05% | 14 |
|
|
2023
Q2 | $22.4M | Buy |
312,408
+21,636
| +7% | +$1.6M | 2.09% | 13 |
|
|
2023
Q1 | $17.9M | Sell |
290,772
-27,839
| -9% | -$1.83M | 1.47% | 18 |
|
|
2022
Q4 | $24.6M | Sell |
318,611
-82,497
| -21% | -$4.93M | 2.37% | 15 |
|
|
2022
Q3 | $17.9M | Sell |
401,108
-141,770
| -26% | -$7.08M | 1.78% | 23 |
|
|
2022
Q2 | $20.8M | Buy |
542,878
+25,298
| +5% | +$800K | 1.7% | 24 |
|
|
2022
Q1 | $21.4M | Sell |
517,580
-92,484
| -15% | -$2.87M | 1.49% | 27 |
|
|
2021
Q4 | $23M | Sell |
610,064
-813,589
| -57% | -$29.9M | 1.41% | 32 |
|
|
2021
Q3 | $46.9M | Sell |
1,423,653
-891,610
| -39% | -$34.7M | 1.43% | 32 |
|
|
2021
Q2 | $156M | Sell |
2,315,263
-95,340
| -4% | -$5.72M | 2.73% | 11 |
|
|
2021
Q1 | $136M | Buy |
2,410,603
+346,445
| +17% | +$24.4M | 2.33% | 15 |
|
|
2020
Q4 | $168M | Buy |
2,064,158
+341,335
| +20% | +$25.5M | 3.06% | 8 |
|
|
2020
Q3 | $123M | Buy |
1,722,823
+636,987
| +59% | +$49.6M | 2.68% | 15 |
|
|
2020
Q2 | $89.3M | Sell |
1,085,836
-86,178
| -7% | -$6.63M | 1.97% | 24 |
|
|
2020
Q1 | $69M | Buy |
1,172,014
+517,775
| +79% | +$42.2M | 1.67% | 27 |
|
|
2019
Q4 | $67.6M | Buy |
654,239
+566,738
| +648% | +$22.9M | 1.11% | 37 |
|
|
2019
Q3 | $1.77M | Sell |
87,501
-7,100
| -8% | -$182K | 0.03% | 49 |
|
|
2019
Q2 | $2.44M | Buy |
94,601
+57,471
| +155% | +$1.15M | 0.04% | 51 |
|
|
2019
Q1 | $528K | Buy |
+37,130
| New | +$345K | 0.01% | 67 |
|
Other funds holding AXSM
Iridian Asset Management's AXSM Position: Q3 2026 in Review
Iridian Asset Management reduced its Axsome Therapeutics (AXSM) stake by 5.8% in Q3 2026, selling an estimated $608K and leaving 45,129 shares worth $8.32M. The position accounts for 3.03% of the portfolio, ranked #9.
Iridian Asset Management first reported a position in AXSM in Q1 2019 and has held it in 31 quarters since. The position peaked at $168M in Q4 2020. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- Iridian Asset Management held 45,129 shares of Axsome Therapeutics worth $8.32M as of Q3 2026.
- Iridian Asset Management sold 2,795 Axsome Therapeutics shares in Q3 2026, an estimated $608K.
- Axsome Therapeutics made up 3.03% of Iridian Asset Management's portfolio in Q3 2026, its #9 holding.
- Iridian Asset Management first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 31 quarters since.
- Iridian Asset Management's Axsome Therapeutics position peaked at $168M in Q4 2020.
- 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on Iridian Asset Management's 13F filing for Q3 2026, filed 23 Oct 2026.